keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/28808924/a-critical-evaluation-on-moh-current-treatments
#1
REVIEW
Andrea Negro, Martina Curto, Luana Lionetto, Simona Guerzoni, Luigi Alberto Pini, Paolo Martelletti
Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients with episodic migraine develop chronic migraine (CM). CM is characterized by high frequency of the attacks that may result into chronic intake of abortive medications. Nearly, the 70% of CM patients referring to tertiary head centers show acute pain medications overuse that may lead to the development of medication overuse headache (MOH)...
August 15, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28808734/what-is-the-true-catheterization-rate-after-intravesical-onabotulinumtoxina-injection
#2
Devin N Patel, Juzar Jamnagerwalla, Justin Houman, Jennifer T Anger, Karyn S Eilber
INTRODUCTION AND HYPOTHESIS: A known side effect of intravesical onabotulinumtoxinA (Botox®) injection for overactive bladder (OAB) is urinary retention requiring clean intermittent catheterization (CIC), the fear of which deters patients from choosing this therapy. In clinical practice, patients with an elevated postvoid residual (PVR) are often managed by observation only, providing they do not have subjective complaints or contraindications. We sought to determine the true rate of urinary retention requiring CIC in clinical practice...
August 14, 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28808621/von-brunn-s-nests-and-follicular-cystitis-following-intradetrusor-onabotulinumtoxina-injections-for-overactive-bladder
#3
Silpa Nekkanti, Andrew Doering, Debra L Zynger, Andrew F Hundley
A 67-year-old female with refractory OAB was treated with intradetrusor Botox. She subsequently developed multiple papillary bladder lesions with tissue biopsy showing Von Brunn's nests. Von Brunn's nests are benign bladder lesions similar in appearance to a rare urothelial tumor called Nested Variant of Urothelial Carcinoma (NVUC). It is critical that patients with these findings undergo evaluation to rule out the presence of carcinoma. This finding suggests the possibility of a previously unreported adverse reaction in association with intradetrusor Botox...
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28805473/the-impact-of-persistence-with-mirabegron-usage-versus-switching-to-onabotulinumtoxina-on-healthcare-costs-and-resource-utilization-in-patients-with-overactive-bladder-in-the-united-states
#4
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, David Walker, Katherine Gooch
Aims To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the United States who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron. Materials and methods A retrospective observational claims analysis of the OptumHealth Administrative Claims database conducted between April 1, 2012 and September 30, 2015 used medical and pharmacy claims to identify patients with at least one OAB diagnosis who switched from mirabegron to onabotA (onabotA group) or persisted on mirabegron for at least 180 days (mirabegron persisters)...
August 14, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28805237/adult-spasticity-international-registry-study-methodology-and-baseline-patient-health-care-provider-and-caregiver-characteristics
#5
Gerard E Francisco, Daniel S Bandari, Ganesh Bavikatte, Wolfgang H Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi
OBJECTIVE: The main aim of this study was to determine the utilization patterns and effectiveness of onabotulinumtoxinA (Botox®) for treatment of spasticity in clinical practice. DESIGN: An international, multicentre, prospective, observational study at selected sites in North America, Europe, and Asia. PATIENTS: Adult patients with newly diagnosed or established focal spasticity, including those who had previously received treatment with onabotulinum-toxin A...
August 14, 2017: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/28791229/impact-of-bladder-dysfunction-in-the-management-of-post-radical-prostatectomy-stress-urinary-incontinence-a-review
#6
REVIEW
Derek B Hennessey, Nathan Hoag, Johan Gani
Bladder dysfunction is a relatively common urodynamic finding post radical prostatectomy (RP). It can be the sole cause of post prostatectomy incontinence (PPI) or may be found in association with stress urinary incontinence (SUI). The aim of this review is to provide a comprehensive review of the diagnosis and different treatments of post RP bladder dysfunction. A comprehensive literature review using medical search engines was performed. The search included a combination of the following terms, PPI, detrusor overactivity (DO), detrusor underactivity (DU), impaired compliance, anticholinergic, onabotulinumtoxinA (Botox(®)) and sacral neuromodulation (SNM)...
July 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28789780/botulinum-toxin-in-parkinson-disease-tremor-a%C3%A2-randomized-double-blind-placebo-controlled-study-with-a-customized-injection-approach
#7
Shivam Om Mittal, Duarte Machado, Diana Richardson, Divyanshu Dubey, Bahman Jabbari
BACKGROUND: In essential tremor and Parkinson disease (PD) tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor, but many patients (30%-70%) develop moderate to severe hand weakness, limiting the use of onabotulinumtoxinA in clinical practice. OBJECTIVE: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for the treatment of tremor in PD. PATIENTS AND METHODS: In this double-blind, placebo-controlled, crossover trial, 30 patients each received 7 to 12 (mean, 9) IncoA injections into hand and forearm muscles using a customized approach...
August 5, 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28771936/intradetrusor-onabotulinumtoxina-injections-for-refractory-neurogenic-detrusor-overactivity-incontinence-do-we-need-urodynamic-investigation-for-outcome-assessment
#8
Miriam Koschorke, Lorenz Leitner, Helen Sadri, Stephanie C Knüpfer, Ulrich Mehnert, Thomas M Kessler
OBJECTIVE: To evaluate if urinary continence after intradetrusor onabotulinumtoxinA injections is sufficient for appropriate outcome assessment or if urodynamic investigation (UDI) is needed. PATIENTS AND METHODS: A consecutive series of 148 patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity (NDO) incontinence were prospectively evaluated. Patients underwent UDI prior and 6 weeks after onabotulinumtoxinA injections...
August 3, 2017: BJU International
https://www.readbyqxmd.com/read/28766236/the-impact-of-onabotulinumtoxina-on-severe-headache-days-preempt-56-week-pooled-analysis
#9
Manjit Matharu, Rashmi Halker, Patricia Pozo-Rosich, Ronald DeGryse, Aubrey Manack Adams, Sheena K Aurora
BACKGROUND: OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders based on reduction in the frequency of headache days alone. METHODS: Data from the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trial program (a 24-week, 2-treatment cycle, double-blind, randomized, placebo-controlled, parallel-group phase, followed by a 32-week, 3-treatment cycle, open-label phase) were pooled for analysis...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28758415/utilization-and-safety-of-onabotulinumtoxina-for-the-prophylactic-treatment-of-chronic-migraine-from-an-observational-study-in-europe
#10
Manjit Matharu, Julio Pascual, Ingela Nilsson Remahl, Andreas Straube, Arlene Lum, Gudarz Davar, Dawn Odom, Lee Bennett, Christina Proctor, Lia Gutierrez, Elizabeth Andrews, Catherine Johannes
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study in adult patients with chronic migraine treated with onabotulinumtoxinA. Data were collected at the first study injection and approximately every three months for ≤52 weeks for utilization and ≤64 weeks for safety data, and summarized using descriptive statistics...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28752512/medical-treatment-guidelines-for-preventive-treatment-of-migraine
#11
Tzu-Chou Huang, Tzu-Hsien Lai, Treatment Guideline Subcommittee Of Taiwan Headache Society Taiwan Headache Society
The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects...
March 15, 2017: Acta Neurologica Taiwanica
https://www.readbyqxmd.com/read/28751016/sacral-neuromodulation-is-preferred-over-onabotulinumtoxina-injection-for-overactive-bladder-in-women-con
#12
Gregory T Bales
No abstract text is available yet for this article.
July 24, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28751015/sacral-neuromodulation-is-preferred-over-onabotulinumtoxina-injection-for-overactive-bladder-in-women-pro
#13
Stephen R Kraus
No abstract text is available yet for this article.
July 24, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28750504/does-myofascial-and-trigger-point-treatment-reduce-pain-and-analgesic-intake-in-patients-undergoing-onabotulinumtoxina-injection-due-to-chronic-intractable-migraine-a-pilot-single-blind-randomized-controlled-trial
#14
Marialuisa Gandolfi, Christian Geroin, Nicola Valè, Fabio Marchioretto, Andrea Turrina, Eleonora Dimitrova, Stefano Tamburin, Anna Serina, Paola Castellazzi, Andrea Meschieri, François Ricard, Leopold Saltuari, Alessandro Picelli, Nicola Smania
BACKGROUND: Chronic migraine is a disabling disorder associated with myofascial and trigger point disorders in the neck. Pharmacological management is the first line of treatment; however, rehabilitation procedures aimed at lessening symptoms of myofascial and trigger point disorders may add value in the management of headache symptoms. AIM: To evaluate the feasibility of myofascial and trigger point treatment in chronic migraine patients receiving prophylactic treatment with onabotulinumtoxinA...
July 27, 2017: European Journal of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/28750118/modification-of-chin-projection-and-aesthetics-with-onabotulinumtoxina-injection
#15
Amy K Hsu, Andrew S Frankel
Importance: Because of the soft-tissue envelope and the dimensional complexity of the muscular contraction of the mentalis muscle, the projection and shape of the chin is not determined by only the bony projection. In a subset of patients with a seemingly underprojected chin, a hyperactive, high-riding mentalis muscle contributes to a blunted chin contour. Objective: To evaluate the use of onabotulinumtoxinA (botulinum toxin A) for improving chin aesthetics in patients with an underprojected bony chin and a high-riding hyperactive mentalis muscle...
July 27, 2017: JAMA Facial Plastic Surgery
https://www.readbyqxmd.com/read/28745807/long-term-outcomes-and-risks-factors-for-failure-of-intradetrusor-onabotulinumtoxin-a-injections-for-the-treatment-of-refractory-neurogenic-detrusor-overactivity
#16
Charles Joussain, Mélanie Popoff, Véronique Phé, Alexia Even, Pierre-Olivier Bosset, Sandra Pottier, Laetitia Falcou, Jonathan Levy, Isabelle Vaugier, Emmanuel Chartier Kastler, Brigitte Schurch, Pierre Denys
AIMS: Aims of this study were to assess the long-term outcomes of Intradetrusor injection of OnabotulinumtoxinA (Botox® injection) associated with clean intermittent-catheterization (CIC) for the treatment of neurogenic detrusor overactivity (NDO) and to identify risk factors for failure. METHODS: Neurological patients with NDO using CIC who had received Botox® injections between January 2001 and September 2013 were included. Clinical, urodynamic and radiological data were recorded...
July 26, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28733943/onabotulinumtoxina-injections-in-chronic-migraine-targeted-to-sites-of-pericranial-myofascial-pain-an-observational-open-label-real-life-cohort-study
#17
Danièle Ranoux, Gaelle Martiné, Gaëlle Espagne-Dubreuilh, Marlène Amilhaud-Bordier, François Caire, Laurent Magy
BACKGROUND: OnabotulinumtoxinA has proven its efficacy in reducing the number of headache days in chronic migraine (CM) patients. The usual paradigm includes 31 pericranial injection sites with low dose (5 U) per site. The aim of this study is to present the results obtained using a simpler injection protocol of onabotulinumtoxinA, with injection sites targeted to pericranial myofascial sites of pain. METHODS: Observational, open label, real-life, cohort study...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28733805/onabotulinumtoxina-botox-in-the-treatment-of-crow-s-feet-lines-in-japanese-subjects
#18
Kiyonori Harii, Makoto Kawashima, Nobutaka Furuyama, Xiaofang Lei, René Hopfinger, Elisabeth Lee
BACKGROUND: This study evaluated the safety and efficacy of onabotulinumtoxinA in Japanese subjects with crow's feet lines (CFL). METHODS: This phase 3, multicenter, double-blind, randomized study included 2 treatment periods: 6-month placebo-controlled period followed by a 7-month open-label period. In period 1, subjects with moderate to severe CFL received onabotulinumtoxinA 24 U (n = 104) or 12 U (n = 99), or placebo (n = 97). In period 2, placebo subjects switched to onabotulinumtoxinA 24 U or 12 U (double-blind dose)...
July 21, 2017: Aesthetic Plastic Surgery
https://www.readbyqxmd.com/read/28726049/quarterly-repeat-cycles-of-onabotulinumtoxina-in-chronic-migraine-patients-the-benefits-of-the-prolonged-treatment-on-the-continuous-responders-and-quality-of-life-conversion-rate-in-a-real-life-setting
#19
Antonio Santoro, Andrea Fontana, Anna M Miscio, Michele M Zarrelli, Massimiliano Copetti, Maurizio A Leone
OnabotulinumtoxinA was approved for treatment of chronic migraine (CM) after publication of Phase 3 Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. However, the PREEMPT trials lasted only up to 1 year. The main aim of our retrospective study was to evaluate whether a prolonged treatment of onabotulinumtoxinA (18 months, six quarterly cycles) will sustain or further improve the efficacy results and the quality of life achieved at 6 and 12 months. Patients were adults with CM with or without overuse of drugs, with at least six regularly repeat onabotulinumtoxinA treatments, administered according to the PREEMPT protocol...
July 19, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/28723381/efficacy-and-safety-of-onabotulinumtoxina-in-patients-with-urinary-incontinence-due-to-neurogenic-detrusor-overactivity-update-of-the-pivotal-randomised-double-blind-placebo-controlled-trials
#20
Carlos Martins-Silva, Francisco Cruz
Bladder injections of 200U onabotulinumtoxinA have similar efficacy in the treatment of urinary incontinence in patients with multiple sclerosis or spinal cord injury. The effect is maintained in the long term without significant adverse events.
August 2016: European Urology Focus
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"